Expert forum
A cell transportation solution that preserves live circulating tumor cells in patient blood samples.
2017-12-08 08:12來源:原版作者:Stefansson S
BACKGROUND:
Circulating tumor cells (CTCs) are typically collected into CellSave fixative tubes, which kills the cells, but preserves their morphology. Currently, the clinical utility of CTCs is mostly limited to their enumeration. More detailed investigation of CTC biology can be performed on live cells, but obtaining live CTCs is technically challenging, requiring blood collection into biocompatible solutions and rapid isolation which limits transportation options. To overcome the instability of CTCs, we formulated a sugar based cell transportation solution (SBTS) that stabilizes cell viability at ambient temperature. In this study we examined the long term viability of human cancer cell lines, primary cells and CTCs in human blood samples in the SBTS for transportation purposes.
METHODS:
Four cell lines, 5 primary human cells and purified human PBMCs were tested to determine the viability of cells stored in the transportation solution at ambient temperature for up to 7 days. We then demonstrated viability of MCF-7 cells spiked into normal blood with SBTS and stored for up to 7 days. A pilot study was then run on blood samples from 3 patients with metastatic malignancies stored with or without SBTS for 6 days. CTCs were then purified by Ficoll separation/microfilter isolation and identified using CTC markers. Cell viability was assessed using trypan blue or CellTracker? live cell stain.
RESULTS:
Our results suggest that primary/immortalized cell lines stored in SBTS remain ~90% viable for > 72 h. Further, MCF-7 cells spiked into whole blood remain viable when stored with SBTS for up to 7 days. Finally, live CTCs were isolated from cancer patient blood samples kept in SBTS at ambient temperature for 6 days. No CTCs were isolated from blood samples stored without SBTS.
CONCLUSIONS:
In this proof of principle pilot study we show that viability of cell lines is preserved for days using SBTS. Further, this solution can be used to store patient derived blood samples for eventual isolation of viable CTCs after days of storage. Therefore, we suggest an effective and economical transportation of cancer patient blood samples containing live CTCs can be achieved.
(BMC Cancer. 2016 May 6;16:300. )
版權(quán)聲明:
本網(wǎng)站所有注明“來源:“陽普醫(yī)療”的文字、圖片和音視頻資料,版權(quán)均屬于陽普醫(yī)療所有,非經(jīng)授權(quán),任何媒體、網(wǎng)站或個人不得轉(zhuǎn)載,授權(quán)轉(zhuǎn)載時須注明
“來源:陽普醫(yī)療”。本網(wǎng)所有轉(zhuǎn)載文章系出于傳遞更多信息之目的,且明確注明來源和作者,不希望被轉(zhuǎn)載的媒體或個人可與我們聯(lián)系,我們將立即進(jìn)行刪除處理。
下一篇:Biomarkers for small cell lung cancer: neuroendocrine, epithelial and circulating tumour cells.
返回首頁網(wǎng)友評論:
版主信息
昵稱:Mandy Luo
郵箱:mandyluo@improve-medical.com
相關(guān)閱讀
- > 《醫(yī)學(xué)拾萃》2023年12月刊:簡述實驗室信息管理系統(tǒng)發(fā)展歷程
- > 《醫(yī)學(xué)拾萃》2023年10月刊:分析前標(biāo)本處理對神經(jīng)元特異性烯醇化酶(NSE)檢測的影響
- > 《醫(yī)學(xué)拾萃》2023年8月刊:PSA 檢測的標(biāo)本處理、質(zhì)量控制及其臨床應(yīng)用
- > 《醫(yī)學(xué)拾萃》2023年6月刊:真空采血管標(biāo)本放置時間和溫度對常見檢驗項目的影響
- > 《醫(yī)學(xué)拾萃》2023年4月刊:游離 DNA 管使用現(xiàn)狀與展望
- > 《醫(yī)學(xué)拾萃》2023年2月刊:肝素管的臨床適用檢測項目與不適用項
- > 《醫(yī)學(xué)拾萃》2022年12月刊:血清分離技術(shù)及其對臨床生化檢驗結(jié)果的影響
- > 《醫(yī)學(xué)拾萃》2022年10月刊:標(biāo)本處理對心肌肌鈣蛋白測定的影響
- > 《醫(yī)學(xué)拾萃》2022年8月刊:一種新型材料-水凝膠的合成及其應(yīng)用
- > 《醫(yī)學(xué)拾萃》2022年6月刊:RFID 技術(shù)及其在醫(yī)療和標(biāo)本管理中的應(yīng)用與發(fā)展